<img alt="" height="1" width="1" />
Vertex Reports Success In Second Major Hepatitis Drug Study
Wall Street Journal
NEW YORK (Dow Jones)--Vertex Pharmaceuticals Inc. (VRTX) reported the success of the second of three key late-stage studies of hepatitis-C treatment, telaprevir, essentially curing 72% of patients using the drug. ...
Vertex says telaprevir benefits last to 24 weeksBusinessWeek
Vertex: telaprevir could shorten hep C treatmentThe Associated Press
Vertex Pharma&#39;s Investigational Hepatitis C Drug Halves Treatment Time : StudyRTT News
FierceBiotech -TheStreet.com -Reuters India
all 48 news articles &raquo;


More...